TECX
NASDAQTectonic Therapeutic Inc.
News25/Ratings10
News · 26 weeks40-40%
2025-10-262026-04-19
Mix3190d
- Insider19(61%)
- SEC Filings6(19%)
- Other3(10%)
- Leadership2(6%)
- Analyst1(3%)
Latest news
25 items- SECTectonic Therapeutic Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)
- PRTectonic Therapeutic Appoints Jessica Chutter to Board of DirectorsWATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed Jessica Chutter to its Board of Directors, effective June 8, 2026. Ms. Chutter brings more than four decades of experience in global healthcare investment banking, with deep expertise advising biotechnology and pharmaceutical companies on strategic positioning, mergers and acquisitions, and capital markets execution. She is widely recognized as a pioneer in investment
- ANALYSTStifel initiated coverage on Tectonic Therapeutic with a new price targetStifel initiated coverage of Tectonic Therapeutic with a rating of Buy and set a new price target of $75.00
- INSIDERSEC Form 4 filed by Ruddy Marcella K.4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERSEC Form 4 filed by Nader Francois4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERSEC Form 3 filed by new insider Nader Francois3 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERChief Medical Officer Ruddy Marcella K. sold $300,000 worth of shares (10,000 units at $30.00), decreasing direct ownership by 13% to 69,747 units (SEC Form 4)4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERChief Scientific Officer Mcnamara Peter sold $188,935 worth of shares (6,262 units at $30.17) and exercised 2,715 shares at a strike of $3.36, decreasing direct ownership by 6% to 55,285 units (SEC Form 4)4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- SECSEC Form S-8 POS filed by Tectonic Therapeutic Inc.S-8 POS - Tectonic Therapeutic, Inc. (0001681087) (Filer)
- INSIDERChief Executive Officer Reicin Alise was granted 76,500 shares, increasing direct ownership by 33% to 311,547 units (SEC Form 4)4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERChief Business Officer Schwabish Marc was granted 19,500 shares, increasing direct ownership by 76% to 45,314 units (SEC Form 4)4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERChief Scientific Officer Mcnamara Peter sold $77,627 worth of shares (3,299 units at $23.53) and was granted 23,000 shares, increasing direct ownership by 50% to 58,832 units (SEC Form 4)4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERChief Financial Officer Lochner Daniel was granted 26,500 shares, increasing direct ownership by 83% to 58,544 units (SEC Form 4)4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERChief Medical Officer Ruddy Marcella K. was granted 26,500 shares, increasing direct ownership by 50% to 79,747 units (SEC Form 4)4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERAmendment: Chief Executive Officer Reicin Alise bought $52,750 worth of shares (2,500 units at $21.10) (SEC Form 4)4/A - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- PRTectonic Therapeutic to Participate in March Investor ConferencesWATERTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in March 2026. TD Cowen 46th Annual Health Care Conference Date:March 4, 2026Time:11:10 AM ESTLocation:Boston, MAFormat:Fireside ChatPresenters:Alise Reicin, MD, President and Chief Executive OfficerWebcast:Link Leerink Global Healthcare Conference Date:March 11, 2026Time:1:40 PM ESTLocation:M
- SECSEC Form S-8 filed by Tectonic Therapeutic Inc.S-8 - Tectonic Therapeutic, Inc. (0001681087) (Filer)
- SECTectonic Therapeutic Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)
- SECSEC Form 10-K filed by Tectonic Therapeutic Inc.10-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)
- PRTectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business HighlightsAnnounced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction ("PH-HFrEF") in October 2025. Topline results showed TX45 was well tolerated and improved both left heart function and pulmonary hemodynamics in patients with Group 2 PH-HFrEFTX2100 advanced into Phase 1a healthy volunteer clinical trial, randomizing the first subject in February 2026, as a potential treatment for Hereditary Hemorrhagic Telangiectasia ("HHT")TX45 advanced into Phase 2 clinical trial in February 2026 with first site activated and opened for screening patients with Pulmonary Hypertension associate
- SECTectonic Therapeutic Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)
- PRTectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the BoardWATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo
- INSIDERChief Executive Officer Reicin Alise bought $52,750 worth of shares (2,500 units at $21.10), increasing direct ownership by 1% to 237,547 units (SEC Form 4)4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERChief Business Officer Schwabish Marc exercised 4,500 shares at a strike of $2.38, increasing direct ownership by 21% to 25,814 units (SEC Form 4)4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERChief Financial Officer Lochner Daniel bought $129,660 worth of shares (6,000 units at $21.61), increasing direct ownership by 23% to 32,044 units (SEC Form 4)4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)